MedicalResearch.com - Latest news, interviews, and insights into medical research, health and wellness, fitness and addiction.
Author Interviews, Dermatology, Medical Imaging, Melanoma / 14.04.2025

MedicalResearch.com Interview with: Pau Rosés-Gibert, MD Dermatology Department, Hospital Clínic Barcelona University of Barcelona, Fundació Clínic per la recerca biomédica, Institut d’Investigació Biomèdica August Pi i Sunyer, IDIBAPS Diagnosis Dermatologica, Dermavision Solutions Barcelona, Spain and Dermatology Department, Hospital de Figueres, Figueres, Spain MedicalResearch.com: What is the background for this study? Response: Skin cancer monitoring, particularly in high-risk patients with atypical mole syndrome, traditionally relies on total body photography (TBP) combined with digital dermoscopy. This approach, though effective, is slow, labor-intensive, and prone to oversight since clinicians must manually locate and image individual lesions. Recent improvements in automated imaging systems, lighting, and dermoscopy software have raised the potential for fully autonomous systems to streamline this process — leading to the development of the autonomous total body photographic and dermoscopic device tested in this study. (more…)
Author Interviews, Dermatology, JAMA / 15.05.2023

MedicalResearch.com Interview with: Matthew Zirwas, MD Founder, Bexley Dermatology Research Clinic Bexley, OH 43209 MedicalResearch.com: What is the background for this study? How does Roflumilast differ from other treatments for seb derm? Response: Seborrheic dermatitis affects up to 5% of the population globally and can have major impacts on quality of life. Treatment regimens are often complicated given the association of seborrheic dermatitis to hair bearing areas of the body, requiring multiple treatments for different parts of the body. Our phase 2 study aimed to understand the efficacy and safety of once-daily roflumilast foam 0.3% in adults with seborrheic dermatitis on their scalp, face and trunk. Roflumilast foam is a selective and highly potent phosphodiesterase (PDE) 4 inhibition that is being studied for a range of inflammatory skin conditions. (more…)